Killer cell immunoglobulin-like receptor genotype and killer cell immunoglobulin-like receptor-human leukocyte antigen C ligand compatibility affect the severity of hepatitis C virus recurrence after liver transplantation

Liver Transplantation

Volumn 15, Issue 4, 2009, Pages 390-399

  de Arias, Alejandro Espadas ^a   Haworth, Simone Elizabeth ^a   Belli, Luca Saverio ^b   Burra, Patrizia ^c   Pinzello, Giovambattista ^b   Vangell, Marcello ^b   Minola, Ernesto ^b   Guido, Maria ^c   Boccagni, Patrizia ^c   De Feo, Tullia Maria ^a   Torelli, Rosanna ^a   Cardillo, Massimo ^a   Scalamogna, Mario ^a   Poli, Francesca ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HLA C ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL3; KIR2DL3 PROTEIN, HUMAN; LIGAND;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GENE FREQUENCY; GENETIC COMPATIBILITY; GENOTYPE; HEPATITIS C; HISTOPATHOLOGY; HLA MATCHING; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT VIRUS INFECTION; REINFECTION; ALLOTRANSPLANTATION; BIOPSY; CLINICAL TRIAL; GENETICS; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY; HOSPITALIZATION; IMMUNOLOGY; ITALY; LIVER; LIVER CELL CARCINOMA; LIVER TUMOR; MIDDLE AGED; MULTICENTER STUDY; NATURAL KILLER CELL; PATHOLOGY; RECURRENT DISEASE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME; VIROLOGY;

ADULT; BIOPSY; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; FEMALE; GENE FREQUENCY; GENOTYPE; GRAFT REJECTION; GRAFT SURVIVAL; HEPATITIS C, CHRONIC; HISTOCOMPATIBILITY; HLA-C ANTIGENS; HUMANS; ITALY; KILLER CELLS, NATURAL; LIGANDS; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RECEPTORS, KIR; RECEPTORS, KIR2DL3; RECURRENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 67649241052     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21673     Document Type: Article

References (54)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005;5:558-567.
2. Berenguer M, López-Labrador FX, Wright TL. Hepatitis C and liver transplantation. J Hepatol 2001;35:666-678.
3. Féray C, Caccamo L, Alexander GJ, Ducot B, Gugenheim J, Casanovas, et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology 1999; 117:619-625.
4. Charlton M, Seaberg E, Wiesner R, Everhart J, Zetterman R, Lake J, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998;28:823-830.
5. Thio CL, Gao X, Goedert JJ, Vlahov D, Nelson KE, Hilgartner MW, et al. HLA-Cw*04 and hepatitis C virus persistence. J Virol 2002; 76:4792-4797.
6. Khakoo SI, Thio CL, Martin MP, Brooks CR, Gao X, Astemborski J, et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 2004;305: 872-874.
7. Mandelboim O, Reyburn HT, Valés-Gómez M, Pazmany L, Colonna M, Borsellino G, et al. Protection from lysis by natural killer cells of group 1 and 2 specificity is mediated by residue 80 in human histocompatibility leukocyte antigen C alleles and also occurs with empty major histocompatibility complex molecules. J Exp Med 1996;184:913-922.
8. Falk CS, Schendel DJ. HLA-C revisited. Ten years of change. Immunol Res 1997;16:203-214.
9. Pende D, Biassoni R, Cantoni C, Verdiani S, Falco M, di Donato C, et al. The natural killer cell receptor specific for HLA-A allotypes: a novel member of the p58/p70 family of inhibitory receptors that is characterized by three immunoglobulin-like domains and is expressed as a 140-kD disulphide-linked dimer. J Exp Med 1996;184:505-518.
10. Carrington M, Martin MP. The impact of variation at the KIR gene cluster on human disease. Curr Top Microbiol Immunol 2006;298:225-257.
11. Hawes SE, Kiviat NB. Are genital infections and inflammation cofactors in the pathogenesis of invasive cervical cancer? J Natl Cancer Inst 2002;94:1592-1593.
12. López-Vázquez A, Rodrigo L, Martínez-Borra J, Pérez R, Rodríguez M, Fdez-Morera JL, et al. Protective effect of the HLA-Bw4I80 epitope and the killer cell immunoglobulin-like receptor 3DS1 gene against the development of hepatocellular carcinoma in patients with hepatitis C virus infection. J Infect Dis 2005; 192:162-165.
13. Winter CC, Gumperz JE, Parham P, Long EO, Wagtmann N. Direct binding and functional transfer of NK cell inhibitory receptors reveal novel patterns of HLA-C allotype recognition. J Immunol 1998;161:571-577.
14. Ahlensteil G, Martin MP, Gao X, Carrington M, Rehermann B. Distinct KIR/ HLA compound genotypes affect the kinetics of human antiviral natural killer cell responses. J Clin Invest 2008;118:1017-1026.
15. Moya-Quiles MR, Muro M, Torío A, Sánchez-Bueno F, Miras M, Marín L, et al. Human leukocyte antigen-C in short- and long-term liver graft acceptance. Liver Transpl 2003;9:218-227.
16. Bishara A, Brautbar C, Zamir G, Eid A, Safadi R. Impact of HLA-C and Bw epitopes disparity on liver transplantation outcome. Hum Immunol 2005;66:1099-1105.
17. Yilmaz N, Shiffman ML, Stravitz RT, Sterling RK, Luketic VA, Sanyal AJ, et al. A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation. Liver Transpl 2007; 13:975-983.
18. Belli LS, Burra P, Poli F, Battista Alberti A, Silini E, Zavaglia C, et al. HLA-DRB1 donor-recipient mismatch affects the outcome of hepatitis C disease recurrence after liver transplantation. Gastroenterology 2006;130:695-702.
19. Sirchia G, Poli F, Cardillo M, Scalamogna M, Rebulla P, Taioli E, et al. A cadaver kidney allocation in the North Italy transplant program on the eve of the new millennium. Clin Transpl 1998:133-145.
20. Ishak K. Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-699.
21. Stern M, Elsässer H, Hönger G, Steiger J, Schaub S, Hess C. The number of activating KIR genes inversely correlates with the rate of CMV infection/reactivation in kidney transplant recipients. Am J Transplant 2008;8:1312-1317.
22. Tran TH, Mytilineos J, Scherer S, Laux G, Middleton D, Opelz G. Analysis of KIR ligand incompatibility in human renal transplantation. Transplantation 2005;80:1121-1123.
23. Bontadini A, Testi M, Cuccia MC, Martinetti M, Carcassi C, Chiesa A, et al. Distribution of killer cell immunoglobulin-like receptors genes in the Italian Caucasian population. J Transl Med 2006;4:44.
24. Martinetti M, Degioanni A, D'Aronzo AM, Benazzi E, Carpanelli R, Castellani L, et al. An immunogenetic map of Lombardy (Northern Italy). Ann Hum Genet 2002;66:37-48.
25. Svejgaard A, Ryder LP. HLA and disease associations: detecting the strongest association. Tissue Antigens 1994; 43:18-27.
26. Alric L, Fort M, Izopet J, Vinel JP, Bureau C, Sandre K, et al. Study of host- and virus-related factors associated with spontaneous hepatitis C virus clearance. Tissue Antigens 2000;56:154-158.
27. Moya-Quiles MR, Alvarez R, Miras M, Gomez-Mateo J, Lopez-Alvarez MR, Marin-Moreno I, et al., for the Spanish Group of Transplant Immunology and Immunotolerance (G03/104). Impact of recipient HLA-C in liver transplant: a protective effect of HLA-Cw*07 on acute rejection. Hum Immunol 2007;68:51-58.
28. Garcia RF, Garcia CE, McMaster P. Chronic rejection of the liver: the role of immunosuppression. BioDrugs 2000; 14:283-297.
29. Ghobrial RM, Farmer DG, Baquerizo A, Colquhoun S, Rosen HR, Yersiz H, et al. Orthotopic liver transplantation for hepatitis C: outcome, effect of immunosuppression, and causes of retransplantation during an 81-year single-center experience. Ann Surg 1999;229:824-831.
30. Piscaglia F; Cucchetti A, Benlloch S, Vivarelli M, Berenguer J. Bolondi L, et al. Prediction of significant fibrosis in hepatitis C virus infected liver transplant recipients by artificial neural network analysis of clinical factors. Eur J Gastroenterol Hepatol 2006; 18:1255-1261.
31. McCaughan GW, Zekry A. Pathogenesis of hepatitis C virus recurrence in the liver allograft. Liver Transpl 2002; 8(suppl 1):S7-S13.
32. Ahmad A, Alvarez F. Role Of NK and NKT cells in the immunopathogenesis of HCV-induced hepatitis. J Leukoc Biol 2004;76:743-759.
33. Elliot LN, Lloyd-AR, Ziegler JB, French RA. Protective immunity against hepatitis C virus infection. Immunol Cell Biol 2006;84:239-249.
34. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002 15;295:2097-2100.
35. Giebel S, Locatelli F, Lamparelli T, Velardi A, Davies S, Frumento G, et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 2003;102:814-819.
36. O'Connor GM, Guinan KJ, Cunningham RT, Middleton D, Parham P, Gardiner CM. Functional polymorphism of the KIR3DL1/S1 receptor on human NK cells. J Immunol 2007;178:235-241.
37. Liao NS, Bix M, Zijlstra M, Jaenisch R, Raulet D. MHC class I deficiency: susceptibility to natural killer (NK) cells and impaired NK activity. Science 1991;253:199-202.
38. Donaldson P, Underhill J, Doherty D, Hayllar K, Calne R, Tan KC, et al. Influence of human leukocyte antigen matching on liver allograft survival and rejection: "the dualistic effect". Hepatology 1993;17:1008-1015.
39. Ciccorossi P, Maina AM, Oliveri F, Petruccelli S, Leandro G, Colombatto P, et al. Viral load 1 week after liver transplantation, donor age and rejections correlate with the outcome of recurrent hepatitis C. Liver Int 2007;27:612-619.
40. Chazouilleres O, Kim M, Combs C, Ferrell L, Bacchetti P, Roberts J, et al. Quantitation of hepatitis C virus RNA in liver transplant recipients. Gastroenterology 1994; 106:994-999.
41. Gane EJ, Naoumov NV. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996;110:167-177.
42. Liu ZX, Govindarajan S, Okamoto S, Dennert G. NK cells cause liver injury and facilitate the induction of T cell-mediated immunity to a viral liver infection. J Immunol 2000;164:6480-6486.
43. Hanada K, Tanaka Y, Mizokami M, Gojobori T, Alter HJ. A reduction in selective immune pressure during the course of chronic hepatitis C correlates with diminished biochemical evidence of hepatic inflammation. Virology 2007;361: 27-33.
44. Bonorino P, Leroy V, Dufeu-Duchesne T, Tongiani-Dashan S, Sturm N, Pernollet M, et al. Features and distribution of CD8 T cells with human leukocyte antigen class I-specific receptor expression in chronic hepatitis C. Hepatology 2007;46:1375-1386.
45. Paladino N, Flores AC, Marcos CY, Fainboim H, Theiler G, Arruvito L, et al. Increased frequencies of activating natural killer receptors are associated with liver injury in individuals who do not eliminate hepatitis C virus. Tissue Antigens 2007;69(suppl 1):109-111.
46. Berenguer M, Prieto M, Palau A, Rayón JM, Carrasco D, Juan FS, et al. Severe recurrent hepatitis C after liver retransplantation for hepatitis C virus-related graft cirrhosis. Liver Transpl 2003;9:228-235.
47. Wright HI, Gavaler JS, Van Theil DH. Preliminary experience with alpha-2b-interferon therapy of viral hepatitis in liver allograft recipients. Transplantation 1992;53:121-124.
48. Oertel M, Kohlhaw K, Diepolder HM, Schröder S, Schwarz R, Tannapfel A, et al. Alloreactivity of natural killer cells in allogeneic liver transplantation. Transplantation 2001:72. 116-122.
49. Bruno S, Crosignani A, Maisonneuve P, Rossi S, Silini E, Mondelli MU. Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study. Hepatology 2007:46:1350-1356.
50. Bruno S, Silini E, Crosignani A, Borzio F, Leandro G, Bono F, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology; 25:754-758.
51. Silini E, Bottelli R, Asti M, Bruno S, Candusso ME, Brambilla S, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a case-control study. Gastroenterology 1996;111:199-205.
52. Missale G, Cariani E, Lamonaca V, Ravaggi A, Rossini A, Bertoni R, et al. Effects of interferon treatment on the antiviral T-cell response in hepatitis C virus genotype 1b-and genotype 2c-infected patients. Hepatology 1997;26: 792-797.
53. Iacob S, Cicinnati VR, Hilgard P, Iacob RA, Gheorghe LS, Popescu I, et al. Predictors of graft and patient survival in hepatitis C virus (HCV) recipients: model to predict HCV cirrhosis after liver transplantation. Transplantation 2007;84:56-63.
54. Botha JF, Thompson E, Gilroy R, Grant WJ, Mukherjee S, Lyden ER, et al. Mild donor liver steatosis has no impact on hepatitis C virus fibrosis progression following liver transplantation. Liver Int 2007:27:758-763.